Literature DB >> 15736066

Standardization of bone marrow features--does it work in hematopathology for histological discrimination of different disease patterns?

J Thiele1, H M Kvasnicka, V Diehl.   

Abstract

Standardized bone marrow (BM) features determined by semiquantitative scoring are valuable tools for the recognition and easily reproducible interpretation of histological patterns in hematopathology. This procedure may help to characterize various disease entities, but especially to differentiate chronic myeloproliferative disorders (MPDs) with increased platelet counts from reactive thrombocytosis (RTh). A clear-cut separation of these conditions continues to present a major problem in hematology. Therefore MPDs are a most suitable model to test the diagnostic relevance of this procedure. By regarding the literature and based on archive material that involved BM biopsies of 319 patients, a semiquantitative grading of histological parameters was performed. Standardized features were applied for a stepwise discriminant analysis to establish different sets of variables exerting a diagnostic impact. A distinction into five histological patterns was achieved that showed a correctly predicted group membership of about 94 %. These were consistent with the clinicopathological diagnosis of polycythemia vera, essential thrombocythemia (ET), prefibrotic or early fibrotic chronic idiopathic myelofibrosis (CIMF) and finally RTh. Variables of discriminating potency according to their ranking included megakaryopoiesis (maturation defects, nuclear lobulation, naked and bulbous nuclei, small and giant size), reticulin fibers, erythro- and granulopoiesis (left shifting and quantity) and cellularity. These findings are in keeping with the assumption that characteristic patterns of BM histopathology can be assigned to different subtypes of MDPs mimicking ET. Discrimination between ET and especially early stage CIMF with thrombocythemia is warranted because of significant implications concerning therapeutic strategies, follow-up examinations and survival. Regarding these results, a schematic procedure is proposed to be used for daily routine diagnosis concerning the discrimination of MPDs.

Entities:  

Mesh:

Year:  2005        PMID: 15736066     DOI: 10.14670/HH-20.633

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  10 in total

Review 1.  Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Authors:  R Tamari; T I Mughal; D Rondelli; R Hasserjian; V Gupta; O Odenike; V Fauble; G Finazzi; F Pane; J Mascarenhas; J Prchal; S Giralt; R Hoffman
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

Review 2.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 3.  Novel insights into the biology and treatment of chronic myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Tiziano Barbui; Omar Abdel-Wahab; Robert Kralovics; Catriona Jamieson; Hans-Michael Kvasnicka; Ann Mullaly; Raajit Rampal; Ruben Mesa; Jean-Jacques Kiladjian; Michael Deininger; Josef Prchal; Rüdiger Hehlmann; Giuseppe Saglio; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-11-19

Review 4.  Rethinking the diagnostic criteria of polycythemia vera.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Leukemia       Date:  2013-12-19       Impact factor: 11.528

5.  The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Authors:  Juergen Thiele; Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

Review 6.  Is it justified to perform a bone marrow biopsy examination in sustained erythrocytosis?

Authors:  Juergen Thiele; Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

Review 7.  The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.

Authors:  Tiziano Barbui; Jürgen Thiele; Heinz Gisslinger; Hans Michael Kvasnicka; Alessandro M Vannucchi; Paola Guglielmelli; Attilio Orazi; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-02-09       Impact factor: 11.037

8.  Philadelphia-negative chronic myeloproliferative neoplasms.

Authors:  Rosane Isabel Bittencourt; Jose Vassallo; Maria de Lourdes Lopes Ferrari Chauffaille; Sandra Guerra Xavier; Katia Borgia Pagnano; Ana Clara Kneese Nascimento; Carmino Antonio De Souza; Carlos Sergio Chiattone
Journal:  Rev Bras Hematol Hemoter       Date:  2012

Review 9.  Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Blood Cancer J       Date:  2015-08-14       Impact factor: 11.037

10.  Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.

Authors:  Hans Michael Kvasnicka; Jürgen Thiele; Carlos E Bueso-Ramos; William Sun; Jorge Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal:  J Hematol Oncol       Date:  2018-03-15       Impact factor: 17.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.